| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | -0.032 | 0.5 |
| mRNA | Nilotinib | CCLE | pan-cancer | AAC | -0.028 | 0.6 |
| mRNA | 17-AAG | CCLE | pan-cancer | AAC | 0.026 | 0.6 |
| mRNA | Crizotinib | CCLE | pan-cancer | AAC | -0.025 | 0.6 |
| mRNA | Nutlin-3 | CCLE | pan-cancer | AAC | 0.026 | 0.6 |
| mRNA | Irinotecan | CCLE | pan-cancer | AAC | 0.028 | 0.6 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | 0.022 | 0.6 |
| mRNA | paclitaxel | CCLE | pan-cancer | AAC | -0.016 | 0.7 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | -0.014 | 0.8 |
| mRNA | AZD0530 | CCLE | pan-cancer | AAC | 0.01 | 0.8 |